BPS804
Sponsors
Ultragenyx Pharmaceutical Inc
Conditions
Chronic-kidney Disease Stage 5D on Stable HemodialysisHypophosphatasiaOsteogenesis Imperfecta
Phase 2
Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)
CompletedNCT01406977
Start: 2011-07-31End: 2012-09-30Updated: 2022-09-16
Safety, Pharmacokinetics and Pharmacodynamics of BPS804 in Osteogenesis Imperfecta
CompletedNCT01417091
Start: 2011-06-30End: 2012-12-31Updated: 2021-05-11
Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease
WithdrawnNCT01806610
Start: 2013-08-31End: 2014-04-30Updated: 2022-09-14
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
WithdrawnNCT03216486
Start: 2017-10-31End: 2018-11-01Updated: 2023-07-03